title: Selenium modulation of cell proliferation and cell cycle biomarkers in normal and premalignant cells of the rat mammary gland.
abstract: The present study was designed to assess the effect of Se-methylselenocysteine or triphenylselenonium chloride treatment on cell proliferation [bromodeoxyuridine (BrdUrd) labeling] and cell cycle biomarkers [proliferating cell nuclear antigen (PCNA), cyclin D1, and p27/Kip 1] in the intact mammary gland of rats. Immunohistochemical assays of the above end points were carried out in different morphological structures: (a) terminal end bud cells and alveolar cells of a maturing mammary gland undergoing active differentiation; and (b) premalignant mammary intraductal proliferations (IDPs) identified at 6 weeks after carcinogen dosing. Neither compound was found to affect BrdUrd labeling or the expression of cell cycle biomarkers in the normal terminal-end bud cells and alveolar cells. Se-methylselenocysteine reduced the total number of IDP lesions by approximately 60%. Interestingly, this was not accompanied by decreases in BrdUrd labeling or the proportion of IDP cells expressing PCNA and cyclin D1. An enhancement in the fraction of p27/Kip 1-positive IDP cells, however, was detected as a result of Se-methylselenocysteine treatment. Although triphenylselenonium chloride did not reduce the total number of IDPs, there were more of the smaller-sized lesions and fewer of the larger-sized lesions compared with those found in the control group. Triphenylselenonium chloride also significantly decreased the proportion of IDP cells incorporating the BrdUrd label or expressing PCNA and cyclin D1. The above findings suggest that early transformed cells are sensitive to selenium intervention, whereas normal proliferating cells are not. It is possible that Se-methylselenocysteine blocks carcinogenesis by a pathway that may not involve cell growth inhibition as a primary response; in contrast, triphenylselenonium chloride is likely to act by a cytostatic mechanism. The data also imply that selenium efficacy testing in intervention trials is possible with the use of biomarkers, provided that the appropriate biomarkers are matched with the selenium compound of interest and that the pathological characteristics of the cell population to be evaluated are taken into consideration.
authors.affiliation: Department of Experimental Pathology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA. cip@sc3101.med.buffalo.edu
authors.forename: C
authors.initials: C
authors.lastname: Ip
authors.forename: H J
authors.initials: HJ
authors.lastname: Thompson
authors.forename: H E
authors.initials: HE
authors.lastname: Ganther
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000963:Antimetabolites; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015415:Biomarkers / Q000032:analysis; D001973:Bromodeoxyuridine; D002453:Cell Cycle / Q000187:drug effects; D018797:Cell Cycle Proteins; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D018890:Chemoprevention; D004396:Coloring Agents; D056741:Cyclin D; D050760:Cyclin-Dependent Kinase Inhibitor p27; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors; D016213:Cyclins / Q000032:analysis; D003545:Cysteine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000032:analysis; D005260:Female; D008321:Mammary Glands, Animal / Q000166:cytology / Q000187:drug effects*; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D008869:Microtubule-Associated Proteins / Q000032:analysis; D016566:Organoselenium Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D011230:Precancerous Conditions / Q000188:drug therapy* / Q000473:pathology; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D017279:Selenocysteine / Q000031:analogs & derivatives; D025521:Tumor Suppressor Proteins
chemical_list: D016588:Anticarcinogenic Agents; D000963:Antimetabolites; D000970:Antineoplastic Agents; D015415:Biomarkers; C493962:Cdkn1b protein, rat; D018797:Cell Cycle Proteins; D004396:Coloring Agents; D056741:Cyclin D; D016213:Cyclins; D004791:Enzyme Inhibitors; D008869:Microtubule-Associated Proteins; D016566:Organoselenium Compounds; D018809:Proliferating Cell Nuclear Antigen; D025521:Tumor Suppressor Proteins; C092819:triphenylselenonium chloride; D017279:Selenocysteine; D050760:Cyclin-Dependent Kinase Inhibitor p27; D018844:Cyclin-Dependent Kinases; D001973:Bromodeoxyuridine; D003545:Cysteine; C002979:selenomethylselenocysteine